Pediatric multiple sclerosis
AB Kornbluh, I Kahn - Seminars in Pediatric Neurology, 2023 - Elsevier
The current diagnostic criteria for pediatric onset multiple sclerosis (POMS) are summarized,
as well as the evidence for performance of the most recent iteration of McDonald criteria in …
as well as the evidence for performance of the most recent iteration of McDonald criteria in …
Neutrophil Nanovesicle protects against experimental autoimmune encephalomyelitis through enhancing myelin clearance by microglia
S Shen, X Cheng, L Zhou, Y Zhao, H Wang, J Zhang… - ACS …, 2022 - ACS Publications
Timely clearance of myelin debris is the premise of neuroinflammation termination and
tissue regeneration in multiple sclerosis (MS). Microglia are the main scavengers of myelin …
tissue regeneration in multiple sclerosis (MS). Microglia are the main scavengers of myelin …
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis
M Puthenparampil, M Gaggiola, F Rinaldi… - Frontiers in …, 2025 - frontiersin.org
Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter
inflammation, as well as by a higher risk of long-term physical and cognitive disability. The …
inflammation, as well as by a higher risk of long-term physical and cognitive disability. The …
High NEDA and no PIRA in natalizumab-treated patients with pediatric-onset multiple sclerosis
M Puthenparampil, M Gaggiola, M Ponzano… - Neurology …, 2024 - neurology.org
Background and Objectives Although pediatric-onset multiple sclerosis (POMS) is
characterized by a more rapid accumulation of CNS inflammation than adult-onset MS …
characterized by a more rapid accumulation of CNS inflammation than adult-onset MS …
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries
Background High-efficacy disease-modifying therapies have been proven to slow disability
accrual in adults with relapsing–remitting multiple sclerosis. However, their impact on …
accrual in adults with relapsing–remitting multiple sclerosis. However, their impact on …
Comparative effectiveness of natalizumab, fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: A registry-based study
T Spelman, G Simoneau, R Hyde, R Kuhelj… - Neurology, 2024 - AAN Enterprises
Background and Objectives Patients with pediatric-onset multiple sclerosis (POMS) typically
experience higher levels of inflammation with more frequent relapses, and though patients …
experience higher levels of inflammation with more frequent relapses, and though patients …
First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in …
Objectives Long-term immunomodulatory therapy of pediatric onset-multiple sclerosis
(POMS) is based mainly on published case series and internationally agreed guidelines …
(POMS) is based mainly on published case series and internationally agreed guidelines …
Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach
A Ghezzi - Neurology and Therapy, 2024 - Springer
Up to 10 years ago the most common approach to the treatment of pediatric MS (ped-MS)
was to start with IFNB or GA (so-called first-line therapies or moderate-efficacy disease …
was to start with IFNB or GA (so-called first-line therapies or moderate-efficacy disease …
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
A Carotenuto, C Di Monaco, L Papetti, G Borriello… - Journal of …, 2024 - Springer
Abstract Background Pediatric-onset Multiple Sclerosis (POMS) patients show more
inflammatory disease compared with adult-onset MS. However, highly effective treatments …
inflammatory disease compared with adult-onset MS. However, highly effective treatments …
Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: a systematic review of clinical trials and observational studies
K Śladowska, P Moćko, T Brzostek… - Multiple Sclerosis and …, 2025 - Elsevier
Objective This study aimed to review the efficacy and safety profile of disease-modifying
therapies (DMTs) in patients with relapsing pediatric-onset multiple sclerosis (POMS) …
therapies (DMTs) in patients with relapsing pediatric-onset multiple sclerosis (POMS) …